Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 10/20 | 0.62 |
| ▸ | ATP1B1 | P05026 | 10/20 | 0.62 |
| ▸ | ATP1A3 | P13637 | 10/20 | 0.62 |
| ▸ | ATP1B2 | P14415 | 10/20 | 0.62 |
| ▸ | ATP1A2 | P50993 | 10/20 | 0.62 |
| ▸ | ATP1B3 | P54709 | 10/20 | 0.62 |
| ▸ | FXYD2 | P54710 | 10/20 | 0.62 |
| ▸ | ATP1A4 | Q13733 | 10/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | ZFP91 | Q96JP5 | 1/20 | 0.62 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18411185 | 1.00 | ATP1A1 (0.62) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL2257591 | 1.00 | ATP1A1 (0.62) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL14477893 | 0.92 | ATP1A1 (0.63) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL22782060 | 0.91 | ATP1A1 (0.61) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL14477892 | 0.90 | ATP1A1 (0.65) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL14477881 | 0.90 | ATP1A1 (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL1483283 | 0.90 | ATP1A1 (0.66) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL18260593 | 0.89 | ATP1A1 (0.60) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL18269602 | 0.89 | ATP1A1 (0.60) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL14477890 | 0.89 | ATP1A1 (0.63) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619106-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | Neupharma, Inc (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-02-09 | — | — | US | claimed |
| EP-3296313-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO LTD (CN) | 2020-12-16 | — | — | EP | claimed |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | claimed |
| EP-3296313-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Suzhou Neupharma Co., Ltd (CN) | 2018-03-21 | — | — | EP | claimed |
| EP-4619106-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | Neupharma, Inc (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20220339164-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2022-10-27 | — | — | US | disclosed |
| US-20220079957-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (JP) | 2022-03-17 | — | — | US | disclosed |
| US-20210113593-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20210113593-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-02-09 | — | — | US | disclosed |
| US-8334376-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-12-18 | — | — | US | disclosed |
| EP-2523966-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Suzhou Neupharma Co., Ltd (CN) | 2012-11-21 | — | — | EP | disclosed |
| US-20110201584-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-08-18 | — | — | US | disclosed |
| US-20110201584-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-08-18 | — | — | US | disclosed |
| US-20110201584-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-08-18 | — | — | US | disclosed |
| WO-2011085641-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011085641-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912784-B2 | Certain chemical entities, compositions, and methods | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
| US-20210113593-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
| US-20220339164-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
| US-20110201584-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
| US-20220079957-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATP1A1 1503/4885ATP1B1 625/4885ATP1A3 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.